ACC 2018: TREAT Late Breaking Trial

Published: 12 Mar 2018

  • Views:

    Views Icon 511
  • Likes:

    Heart Icon 0

Explore the safety and efficacy of ticagrelor compared with clopidogrel in patients with acute coronary syndrome with ST elevation treated with thrombolysis - ACC 2018


An expert peer-to-peer discussion on the latest data to come out of the TREAT trial and its implications for clinical practice.


Sunday 11th March 2018 @ 15:00 EST
ACC.18 Congress, Orlando, FL
Discussants: Dr Otavio Berwanger (BR) & Prof José C Nicolau (São Paolo, Brazil)



Dr Otavio Berwanger, Director of HCor Heart Hospital, Brazil

Dr Berwanger’s major recent contributions include: Created a Network of 154 Cardiovascular Research Sites in Brazil and 20 sites in Latin America; Built the largest Clinical Trials Unit in South America (Research Institute HCor-Heart Hospital) in Sao Paulo-SP, Brazil.


Prof José C Nicolau, Director of the Clinical Unit of Acute Coronary Disease of the Heart Institute - InCor / HCFMUSP, University of São Paolo, Brazil

Professor Nicolau’s main area of research includes the broad spectrum of coronary artery disease (mainly ACS), including hyperglycemia, LV remodeling, platelet reactivity, and antithrombotic therapy. He has participated in more than 80 international multicenter clinical trials, serving as a member of their steering, executive, or international committees in most of them.